Skip to content

Prospective Evaluation of Therapeutic Combination in Treating Vertebral Compression Fractures

PROTECT - Prospective Evaluation of Therapeutic Combination in Treating Vertebral Compression Fractures

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06670404
Acronym
PROTECT
Enrollment
130
Registered
2024-11-01
Start date
2024-11-06
Completion date
2026-12-31
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Facet Joint Arthropathy, Pathological Fracture, Vertebral Compression Fractures

Keywords

vertebroplasty, CONFIDENCE High Viscosity Spinal Cement, observational post-market study

Brief summary

The purpose of this study is to collect clinical and radiographic outcomes in patients undergoing vertebroplasty procedures for the treatment of osteoporotic or pathological fractures of the vertebral body to understand the role of sagittal balance in patient outcomes. To support this objective, the sagittal balance measurement of sagittal vertical axis (SVA), NRS back pain, Quebec Back Pain Disability Scale (Quebec) score, and complications will be collected. The secondary purpose of the study is to review the role of sagittal balance and adjacent facet joint arthropathy treatment in patients with vertebral body fractures due to osteoporosis or tumor.

Interventions

DEVICEVertebroplasty

Vertebral compression fractures treated with CONFIDENCE High Viscosity Cement

Sponsors

Johnson & Johnson
CollaboratorINDUSTRY
Dr Danoob Dalili
CollaboratorUNKNOWN
Prof Nicolas Theumann
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients \>18 years. * Patients requiring vertebroplasty for the fixation of symptomatic pathological fractures of the thoracic or lumbar vertebral body resulting from osteoporosis or tumor. * Symptomatic vertebral compression fracture(s) confirmed by MRI with bone marrow oedema on T2/STIR sequences. * Diagnosis of osteoporosis (clinically and confirmed on DXA with quantifiable BMD) or pathological fracture due to tumor * Patients with 1 or more vertebral compression fractures of the thoracic or lumbar spine Note: Patients with a current vertebral compression fracture who also have a previous history of vertebral compression fractures of the thoracic or lumbar spine may be included. Study Specific Inclusion Criterion • Signed informed consent

Exclusion criteria

* Infection * Vertebral body collapse to less than 1/3 (33%) of original height * Vertebral plana (\>90% vertebral body collapse) * Spinal stenosis (retro pulsed fragments). * Unstable spine warranting surgical stabilization * Prophylactic treatment of any vertebrae with vertebroplasty * Irreversible life threating bleeding disorders * End stage kidney disease * Drug dependence (IVDU) * Pregnancy Study Specific Exclusion Criterion: • Unable or unwilling to follow the standard of care prescribed follow-up visits

Design outcomes

Primary

MeasureTime frameDescription
Improvement of sagittal balanceUp to 12 months post index surgerymeasurement of sagittal vertical axis (SVA)

Secondary

MeasureTime frameDescription
Improvement in Back PainUp to 12 months post index surgeryMeasured as NRS scale for back pain
Quebec Score6-12 months post index surgeryMeasured as the standard Quebec Score
ComplicationsUp to 12 months post-index surgery

Countries

Switzerland

Contacts

Primary ContactNicolas Prof Theumann, Medical Doctor
nicolas.theumann@hirslanden.ch0041795251859

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026